Cargando…
Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report
BACKGROUND: Atezolizumab is a programmed death ligand 1 (PD-L1) inhibitor, and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma (HCC). Treatment with immune checkpoint inhibitors (ICIs) can lead to hypersensitivity reactions; howev...
Autores principales: | Bian, Li-Fang, Zheng, Chao, Shi, Xiao-Lan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180205/ https://www.ncbi.nlm.nih.gov/pubmed/34141773 http://dx.doi.org/10.12998/wjcc.v9.i16.4110 |
Ejemplares similares
-
Anaphylactic Shock
por: Ghosh, P. K.
Publicado: (1949) -
Sugammadex-induced anaphylactic shock
por: Kim, Ha-Jung, et al.
Publicado: (2020) -
Carbimazole-induced Anaphylactic Shock: A Case Report
por: Keyal, Niraj Kumar, et al.
Publicado: (2019) -
Cefixime: Anaphylactic shock: case report
Publicado: (2020) -
ANAPHYLACTIC SHOCK BY AZODYES
por: Landsteiner, K., et al.
Publicado: (1933)